Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold

Executive Summary

The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.

You may also be interested in...



Gilead Sees HIV Business Return To Sales Growth As Oncology Gets Boost

The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.

ViiV Readies Entry To HIV PrEP Market After Apretude Approval

A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel